Language of the Report – English
Sin embargo, el informe puede estar disponible en español por un costo adicional.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Nuclear Medicine Market Overview
3.1 Global Nuclear Medicine Market Historical Value (2019-2025)
3.2 Global Nuclear Medicine Market Forecast Value (2026-2035)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Global Nuclear Medicine Market Landscape*
5.1 Global Nuclear Medicine Market: Developers Landscape
5.1.1 Analysis by Year of Establishment
5.1.2 Analysis by Company Size
5.1.3 Analysis by Region
5.2 Global Nuclear Medicine Market: Product Landscape
5.2.1 Analysis by Type
5.2.2 Analysis by Application
6 Global Nuclear Medicine Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
6.2.1 Strengths
6.2.2 Weaknesses
6.2.3 Opportunities
6.2.4 Threats
6.3 PESTEL Analysis
6.3.1 Political
6.3.2 Economic
6.3.3 Social
6.3.4 Technological
6.3.5 Legal
6.3.6 Environment
6.4 Porter’s Five Forces Model
6.4.1 Bargaining Power of Suppliers
6.4.2 Bargaining Power of Buyers
6.4.3 Threat of New Entrants
6.4.4 Threat of Substitutes
6.4.5 Degree of Rivalry
6.5 Key Demand Indicators
6.6 Key Price Indicators
6.7 Industry Events, Initiatives, and Trends
6.8 Value Chain Analysis
7 Global Nuclear Medicine Market Segmentation (2019-2035)
7.1 Global Nuclear Medicine Market (2019-2035) by Type
7.1.1 Market Overview
7.1.2 Diagnostic Nuclear Medicine
7.1.2.1 SPECT (Single-Photon Emission Computed Tomography)
7.1.2.1.1 Tc-99m
7.1.2.1.2 I-123
7.1.2.1.3 Tl-201
7.1.2.1.4 Ga-67
7.1.2.1.5 Other SPECT isotopes
7.1.2.2 PET (Positron Emission Tomography) Radiopharmaceuticals
7.1.2.2.1 F-18
7.1.2.2.2 Rb-82
7.1.2.2.3 Others
7.1.3 Therapeutic Nuclear Medicine
7.1.3.1 Alpha Emitters
7.1.3.1.1 Ra-223
7.1.3.2 Beta Emitters
7.1.3.2.1 I-131
7.1.3.2.2 Y-90
7.1.3.2.3 Sm-153
7.1.3.2.4 Lu-177
7.1.3.2.5 Re-186
7.1.3.2.6 Others
7.1.3.3 Brachytherapy Isotopes
7.1.3.3.1 I-125
7.1.3.3.2 Ir-192
7.1.3.3.3 Pd-103
7.1.3.3.4 Cs-131
7.1.3.3.5 Others
7.2 Global Nuclear Medicine Market (2019-2035) by Application
7.2.1 Market Overview
7.2.2 Oncology
7.2.3 Cardiology
7.2.4 Neurology
7.2.5 Thyroid Indications
7.2.6 Bone Diseases
7.2.7 Others
7.3 Global Nuclear Medicine Market (2019-2035) by End User
7.3.1 Market Overview
7.3.2 Hospitals & Clinics
7.3.3 Diagnostic Centers
7.3.4 Academic and Research Institutes
7.3.5 Others
7.4 Global Nuclear Medicine Market (2019-2035) by Region
7.4.1 Market Overview
7.4.2 North America
7.4.3 Europe
7.4.4 Asia Pacific
7.4.5 Latin America
7.4.6 Middle East and Africa
8 North America Nuclear Medicine Market (2019-2035)
8.1 North America Nuclear Medicine Market (2019-2035) by Type
8.1.1 Market Overview
8.1.2 Diagnostic Nuclear Medicine
8.1.2.1 SPECT (Single-Photon Emission Computed Tomography)
8.1.2.1.1 Tc-99m
8.1.2.1.2 I-123
8.1.2.1.3 Tl-201
8.1.2.1.4 Ga-67
8.1.2.1.5 Other SPECT isotopes
8.1.2.2 PET (Positron Emission Tomography) Radiopharmaceuticals
8.1.2.2.1 F-18
8.1.2.2.2 Rb-82
8.1.2.2.3 Others
8.1.3 Therapeutic Nuclear Medicine
8.1.3.1 Alpha Emitters
8.1.3.1.1 Ra-223
8.1.3.2 Beta Emitters
8.1.3.2.1 I-131
8.1.3.2.2 Y-90
8.1.3.2.3 Sm-153
8.1.3.2.4 Lu-177
8.1.3.2.5 Re-186
8.1.3.2.6 Others
8.1.3.3 Brachytherapy Isotopes
8.1.3.3.1 I-125
8.1.3.3.2 Ir-192
8.1.3.3.3 Pd-103
8.1.3.3.4 Cs-131
8.1.3.3.5 Others
8.2 North America Nuclear Medicine Market (2019-2035) by Application
8.2.1 Market Overview
8.2.2 Oncology
8.2.3 Cardiology
8.2.4 Neurology
8.2.5 Thyroid Indications
8.2.6 Bone Diseases
8.2.7 Others
8.3 North America Nuclear Medicine Market (2019-2035) by End User
8.3.1 Market Overview
8.3.2 Hospitals & Clinics
8.3.3 Diagnostic Centers
8.3.4 Academic and Research Institutes
8.3.5 Others
8.4 North America Nuclear Medicine Market (2019-2035) by Country
8.4.1 United States of America
8.4.1.1 United States of America Nuclear Medicine Market (2019-2035) by Type
8.4.2 Canada
8.4.2.1 Canada Nuclear Medicine Market (2019-2035) by Type
9 Europe Nuclear Medicine Market (2019-2035)
9.1 Europe Nuclear Medicine Market (2019-2035) by Type
9.1.1 Market Overview
9.1.2 Diagnostic Nuclear Medicine
9.1.2.1 SPECT (Single-Photon Emission Computed Tomography)
9.1.2.1.1 Tc-99m
9.1.2.1.2 I-123
9.1.2.1.3 Tl-201
9.1.2.1.4 Ga-67
9.1.2.1.5 Other SPECT isotopes
9.1.2.2 PET (Positron Emission Tomography) Radiopharmaceuticals
9.1.2.2.1 F-18
9.1.2.2.2 Rb-82
9.1.2.2.3 Others
9.1.3 Therapeutic Nuclear Medicine
9.1.3.1 Alpha Emitters
9.1.3.1.1 Ra-223
9.1.3.2 Beta Emitters
9.1.3.2.1 I-131
9.1.3.2.2 Y-90
9.1.3.2.3 Sm-153
9.1.3.2.4 Lu-177
9.1.3.2.5 Re-186
9.1.3.2.6 Others
9.1.3.3 Brachytherapy Isotopes
9.1.3.3.1 I-125
9.1.3.3.2 Ir-192
9.1.3.3.3 Pd-103
9.1.3.3.4 Cs-131
9.1.3.3.5 Others
9.2 Europe Nuclear Medicine Market (2019-2035) by Application
9.2.1 Market Overview
9.2.2 Oncology
9.2.3 Cardiology
9.2.4 Neurology
9.2.5 Thyroid Indications
9.2.6 Bone Diseases
9.2.7 Others
9.3 Europe Nuclear Medicine Market (2019-2035) by End User
9.3.1 Market Overview
9.3.2 Hospitals & Clinics
9.3.3 Diagnostic Centers
9.3.4 Academic and Research Institutes
9.3.5 Others
9.4 Europe Nuclear Medicine Market (2019-2035) by Country
9.4.1 United Kingdom
9.4.1.1 United Kingdom Nuclear Medicine Market (2019-2035) by Type
9.4.2 Germany
9.4.2.1 Germany Nuclear Medicine Market (2019-2035) by Type
9.4.3 France
9.4.3.1 France Nuclear Medicine Market (2019-2035) by Type
9.4.4 Italy
9.4.4.1 Italy Nuclear Medicine Market (2019-2035) by Type
9.4.5 Others
10 Asia Pacific Nuclear Medicine Market (2019-2035)
10.1 Asia Pacific Nuclear Medicine Market (2019-2035) by Type
10.1.1 Market Overview
10.1.2 Diagnostic Nuclear Medicine
10.1.2.1 SPECT (Single-Photon Emission Computed Tomography)
10.1.2.1.1 Tc-99m
10.1.2.1.2 I-123
10.1.2.1.3 Tl-201
10.1.2.1.4 Ga-67
10.1.2.1.5 Other SPECT isotopes
10.1.2.2 PET (Positron Emission Tomography) Radiopharmaceuticals
10.1.2.2.1 F-18
10.1.2.2.2 Rb-82
10.1.2.2.3 Others
10.1.3 Therapeutic Nuclear Medicine
10.1.3.1 Alpha Emitters
10.1.3.1.1 Ra-223
10.1.3.2 Beta Emitters
10.1.3.2.1 I-131
10.1.3.2.2 Y-90
10.1.3.2.3 Sm-153
10.1.3.2.4 Lu-177
10.1.3.2.5 Re-186
10.1.3.2.6 Others
10.1.3.3 Brachytherapy Isotopes
10.1.3.3.1 I-125
10.1.3.3.2 Ir-192
10.1.3.3.3 Pd-103
10.1.3.3.4 Cs-131
10.1.3.3.5 Others
10.2 Asia Pacific Nuclear Medicine Market (2019-2035) by Application
10.2.1 Market Overview
10.2.2 Oncology
10.2.3 Cardiology
10.2.4 Neurology
10.2.5 Thyroid Indications
10.2.6 Bone Diseases
10.2.7 Others
10.3 Asia Pacific Nuclear Medicine Market (2019-2035) by End User
10.3.1 Market Overview
10.3.2 Hospitals & Clinics
10.3.3 Diagnostic Centers
10.3.4 Academic and Research Institutes
10.3.5 Others
10.4 Asia Pacific Nuclear Medicine Market (2019-2035) by Country
10.4.1 China
10.4.1.1 China Nuclear Medicine Market (2019-2035) by Type
10.4.2 Japan
10.4.2.1 Japan Nuclear Medicine Market (2019-2035) by Type
10.4.3 India
10.4.3.1 India Nuclear Medicine Market (2019-2035) by Type
10.4.4 ASEAN
10.4.4.1 ASEAN Nuclear Medicine Market (2019-2035) by Type
10.4.5 Australia
10.4.5.1 Australia Nuclear Medicine Market (2019-2035) by Type
10.4.6 Others
11 Latin America Nuclear Medicine Market (2019-2035)
11.1 Latin America Nuclear Medicine Market (2019-2035) by Type
11.1.1 Market Overview
11.1.2 Diagnostic Nuclear Medicine
11.1.2.1 SPECT (Single-Photon Emission Computed Tomography)
11.1.2.1.1 Tc-99m
11.1.2.1.2 I-123
11.1.2.1.3 Tl-201
11.1.2.1.4 Ga-67
11.1.2.1.5 Other SPECT isotopes
11.1.2.2 PET (Positron Emission Tomography) Radiopharmaceuticals
11.1.2.2.1 F-18
11.1.2.2.2 Rb-82
11.1.2.2.3 Others
11.1.3 Therapeutic Nuclear Medicine
11.1.3.1 Alpha Emitters
11.1.3.1.1 Ra-223
11.1.3.2 Beta Emitters
11.1.3.2.1 I-131
11.1.3.2.2 Y-90
11.1.3.2.3 Sm-153
11.1.3.2.4 Lu-177
11.1.3.2.5 Re-186
11.1.3.2.6 Others
11.1.3.3 Brachytherapy Isotopes
11.1.3.3.1 I-125
11.1.3.3.2 Ir-192
11.1.3.3.3 Pd-103
11.1.3.3.4 Cs-131
11.1.3.3.5 Others
11.2 Latin America Nuclear Medicine Market (2019-2035) by Application
11.2.1 Market Overview
11.2.2 Oncology
11.2.3 Cardiology
11.2.4 Neurology
11.2.5 Thyroid Indications
11.2.6 Bone Diseases
11.2.7 Others
11.3 Latin America Nuclear Medicine Market (2019-2035) by End User
11.3.1 Market Overview
11.3.2 Hospitals & Clinics
11.3.3 Diagnostic Centers
11.3.4 Academic and Research Institutes
11.3.5 Others
11.4 Latin America Nuclear Medicine Market (2019-2035) by Country
11.4.1 Brazil
11.4.1.1 Brazil Nuclear Medicine Market (2019-2035) by Type
11.4.2 Argentina
11.4.2.1 Argentina Nuclear Medicine Market (2019-2035) by Type
11.4.3 Mexico
11.4.3.1 Mexico Nuclear Medicine Market (2019-2035) by Type
11.4.4 Others
12 Middle East and Africa Nuclear Medicine Market (2019-2035)
12.1 Middle East and Africa Nuclear Medicine Market (2019-2035) by Type
12.1.1 Market Overview
12.1.2 Diagnostic Nuclear Medicine
12.1.2.1 SPECT (Single-Photon Emission Computed Tomography)
12.1.2.1.1 Tc-99m
12.1.2.1.2 I-123
12.1.2.1.3 Tl-201
12.1.2.1.4 Ga-67
12.1.2.1.5 Other SPECT isotopes
12.1.2.2 PET (Positron Emission Tomography) Radiopharmaceuticals
12.1.2.2.1 F-18
12.1.2.2.2 Rb-82
12.1.2.2.3 Others
12.1.3 Therapeutic Nuclear Medicine
12.1.3.1 Alpha Emitters
12.1.3.1.1 Ra-223
12.1.3.2 Beta Emitters
12.1.3.2.1 I-131
12.1.3.2.2 Y-90
12.1.3.2.3 Sm-153
12.1.3.2.4 Lu-177
12.1.3.2.5 Re-186
12.1.3.2.6 Others
12.1.3.3 Brachytherapy Isotopes
12.1.3.3.1 I-125
12.1.3.3.2 Ir-192
12.1.3.3.3 Pd-103
12.1.3.3.4 Cs-131
12.1.3.3.5 Others
12.2 Middle East and Africa Nuclear Medicine Market (2019-2035) by Application
12.2.1 Market Overview
12.2.2 Oncology
12.2.3 Cardiology
12.2.4 Neurology
12.2.5 Thyroid Indications
12.2.6 Bone Diseases
12.2.7 Others
12.3 Middle East and Africa Nuclear Medicine Market (2019-2035) by End User
12.3.1 Market Overview
12.3.2 Hospitals & Clinics
12.3.3 Diagnostic Centers
12.3.4 Academic and Research Institutes
12.3.5 Others
12.4 Middle East and Africa Nuclear Medicine Market (2019-2035) by Country
12.4.1 Saudi Arabia
12.4.1.1 Saudi Arabia Nuclear Medicine Market (2019-2035) by Type
12.4.2 United Arab Emirates
12.4.2.1 United Arab Emirates Nuclear Medicine Market (2019-2035) by Type
12.4.3 Nigeria
12.4.3.1 Nigeria Nuclear Medicine Market (2019-2035) by Type
12.4.4 South Africa
12.4.4.1 South Africa Nuclear Medicine Market (2019-2035) by Type
12.4.5 Others
13 Regulatory Framework
13.1 Regulatory Overview
13.2 US FDA
13.3 EU EMA
13.4 INDIA CDSCO
13.5 JAPAN PMDA
13.6 Others
14 Patent Analysis
14.1 Analysis by Type of Patent
14.2 Analysis by Publication Year
14.3 Analysis by Issuing Authority
14.4 Analysis by Patent Age
14.5 Analysis by CPC Analysis
14.6 Analysis by Patent Valuation
14.7 Analysis by Key Players
15 Clinical Trials Analysis
15.1 Analysis by Trial Registration Year
15.2 Analysis by Trial Status
15.3 Analysis by Trial Phase
15.4 Analysis by Therapeutic Area
15.5 Analysis by Geography
16 Funding and Investment Analysis
16.1 Analysis by Funding Instances
16.2 Analysis by Type of Funding
16.3 Analysis by Funding Amount
16.4 Analysis by Leading Players
16.5 Analysis by Leading Investors
16.6 Analysis by Geography
17 Strategic Initiatives
17.1 Analysis by Partnership Instances
17.2 Analysis by Type of Initiatives
17.3 Analysis by Joint Ventures
17.4 Analysis by Leading Players
17.5 Analysis by Geography
18 Supplier Landscape
18.1 Market Share Analysis, By Region (For Top 5 Companies)
18.1.1 Market Share Analysis: Global
18.1.2 Market Share Analysis: North America
18.1.3 Market Share Analysis: Europe
18.1.4 Market Share Analysis: Asia Pacific
18.1.5 Market Share Analysis: Others
18.2 GE Healthcare
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Company News and Development
18.2.5 Certifications
18.3 Cardinal Health
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Company News and Development
18.3.5 Certifications
18.4 Curium
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Company News and Development
18.4.5 Certifications
18.5 Bayer AG
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Company News and Development
18.5.5 Certifications
18.6 Lantheus Holdings, Inc.
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Company News and Development
18.6.5 Certifications
18.7 Bracco Imaging S.P.A.
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Company News and Development
18.7.5 Certifications
18.8 Pharmalogic Holdings Corp.
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Company News and Development
18.8.5 Certifications
18.9 Nordion Inc.
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Company News and Development
18.9.5 Certifications
18.10 Isotope JSC
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Company News and Development
18.10.5 Certifications
18.11 Siemens Healthineers
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Company News and Development
18.11.5 Certifications
19 Global Nuclear Medicine Market – Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total branded market. The Informes de Expertos (IDE) team strives to make this section as comprehensive as possible.
**The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.